JMP Securities Downgrades LAVA Therapeutics to Market Perform, Maintains Price Target to $6
JMP Securities Downgrades LAVA Therapeutics to Market Perform, Maintains Price Target to $6
JMP證券將LAVA Therapeutics的評級下調至市場表現,維持目標價爲6美元。
JMP Securities analyst Reni Benjamin downgrades LAVA Therapeutics (NASDAQ:LVTX) from Market Outperform to Market Perform and maintains the price target from $6 to $6.
JMP Securities 分析師Reni Benjamin 將LAVA Therapeutics(納斯達克:LVTX)評級從市場跑贏下調至市場表現,並將價格目標維持在6美元不變。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。